Since 2014, UVA Health has been a part of the multi-center Quality Improvement database, Congenital Cardiac Catheterization Project on Outcomes (C3PO), alongside 19 top institutions, including many of the nation’s best pediatric and congenital cardiac programs.
Key achievements for UVA that were noted in the C3PO’s 2023 annual report include:
- The lowest Serious Adverse Event Ratio (SAER) among all participants, with moderate adverse events occurring at only 40% of the expected rate.
- A 17% increase in case volume from 2022, handling complex cases on par with larger institutions.
- Despite representing just 3% of the total case volume, UVA accounted for 14% of atretic valve perforations and 7% of neonatal aortic valvuloplasties in the database.
- UVA surpassed national averages with high-risk hemodynamic vulnerability scores, procedure times 20-30% shorter than the median, and patient radiation exposure 10-40% lower across all procedure categories.
This remarkable success is thanks to the combined efforts of UVA’s nurses, technicians, physicists, physicians, and a dedicated research team. With such impressive results, UVA stands as one of the leading programs for children with congenital heart disease in the U.S.
Filed Under: Clinical